Welcome to our dedicated page for Petmed Express news (Ticker: PETS), a resource for investors and traders seeking the latest updates and insights on Petmed Express stock.
PetMed Express Inc (PETS), America's largest online pet pharmacy, provides this centralized hub for official corporate communications and market-moving developments. Access verified press releases, SEC filings, and strategic announcements from the nation's leading direct-to-consumer pet medication provider.
Investors and industry observers will find comprehensive coverage of financial results, regulatory updates, product innovations, and partnership agreements. Our curated news feed tracks material events impacting PETS' position in the $100B pet healthcare market, including prescription medication approvals and e-commerce platform enhancements.
Key updates include quarterly earnings disclosures, FDA compliance announcements, and distribution network expansions. All content is sourced directly from company filings and official statements to ensure regulatory compliance and factual accuracy.
Bookmark this page for real-time access to PETS' corporate communications, including 8-K filings detailing material events and 10-K annual reports. Check regularly for updates on the company's mission to deliver affordable pet healthcare through its innovative online pharmacy model.
PetMed Express, Inc. (NASDAQ: PETS) has completed the acquisition of PetCareRx for approximately $36 million in cash. This strategic move expands PetMeds' market reach from pet medications to a wider healthcare category. With the addition of around 10,000 new food, diet, and wellness products, PetMeds aims to enhance its product offerings and service capabilities for its over two million active customers. The acquisition will allow PetMeds to leverage a more efficient distribution network while maintaining the independent operation of PetCareRx's e-commerce platform, ensuring continuity in customer experience.
PetMed Express, Inc. (NASDAQ: PETS) reported its financial results for Q3 FY 2023, with net sales of $58.9 million, marking a 3% decline year-over-year. The company recorded a net loss of $19,000, translating to $(0.00) per diluted share, down from a net income of $4.3 million or $0.21 per share in the same quarter last year. Adjusted EBITDA fell 64% to $2.7 million. However, new customers increased by 9% year-over-year, the first rise in 10 quarters. The Board declared a $0.30 quarterly dividend, payable on February 27, 2023. Management believes ongoing investments, including the acquisition of PetCareRx, will foster long-term growth.
PetMed Express (PETS) has announced a conference call scheduled for February 6, 2023, at 4:30 PM Eastern Time to discuss its third-quarter financial results for the period ending December 31, 2022. This call will be preceded by a press release detailing the financial results. Interested parties can join via a U.S. dial-in number or international line, and a replay will be available until February 20, 2023. PetMed Express, founded in 1996, provides prescription and non-prescription medications for pets through its 1-800-PetMeds service and website. Key risks and uncertainties, including the company's ability to fulfill its business objectives, are noted in their SEC filings.
FAQ
What is the current stock price of Petmed Express (PETS)?
What is the market cap of Petmed Express (PETS)?
